Protalix BioTherapeutics Inc

Type: Company
Name: Protalix BioTherapeutics Inc (Protalix Biotherapeutics Inc)
First reported Sep 29 2014 - Updated 21 hours ago - 1 reports

PRE 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

Document Format FilesSeq Description Document Type Size 1 FORM PRE 14A v390196_pre14a.htm PRE 14A 572873 2 GRAPHIC tlogo.jpg GRAPHIC 10707 3 GRAPHIC tsig.jpg GRAPHIC 5051 4 GRAPHIC image_002.gif GRAPHIC 95091 5 GRAPHIC image_004.gif GRAPHIC 24400 Complete ... [Published SEC - Sep 29 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

New Products for pharmacists 10-10-2014

New RxTrulicity image courtesy of Eli Lilly FDA has approved dulaglutide  (Trulicity; Eli Lilly), a once-weekly subcutaneous injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes, which ... [Published Drugtopics.com - Sep 30 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

PROTALIX BIOTHERAPEUTICS : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersOn September 28, 2014 , the Board of Directors of Protalix BioTherapeutics, Inc. (the "Company") ... [Published 4 Traders - Sep 29 2014]
First reported Sep 29 2014 - Updated Sep 29 2014 - 1 reports

Protalix BioTherapeutics names Moshe Manor as CEO

The board of directors of Biopharmaceutical company Protalix BioTherapeutics (NYSE MKT:PLX) reported on Monday the appointment of Moshe Manor as its new president and chief executive officer from 2 November 2014, succeeding Dr Aviezer. Most recently, ... [Published Individual.com - Sep 29 2014]
First reported Sep 25 2014 - Updated Sep 25 2014 - 1 reports

Protalix BioTherapeutics Short Interest Up 1.3% in September (PLX)

Shares of Protalix BioTherapeutics (NYSE:PLX) were the recipient of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 6,182,330 shares, a growth of 1.3% from the August 29th ... [Published American Banking News - Sep 25 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO? taliglucerase alfa for Injection, for Intravenous Use...

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO? taliglucerase alfa for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher DiseaseBy a News Reporter-Staff News Editor at Biotech Week Pfizer ... [Published Pharmacy Choice - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 2 reports

Protalix share price slumps on Ebola vaccine doubts

Shares in Israeli pharmaceutical company Protalix fell on the Tel Aviv Stock Exchange (TASE) yesterday, after comments made by the company's chief executive cast doubts on its ability to develop an anti-Ebola drug quickly and effectively.On Saturday, ... [Published City A.M. - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

With killer virus Ebola out of control, Israel's Protalix shares surge

Ebola was suspected to have spread to countries like Saudi Arabia and even by plane to the United Arab ... ... [Published Wall Street Business Network - Sep 08 2014]
First reported Sep 06 2014 - Updated Sep 07 2014 - 9 reports

BRIEF: Protalix jumps on reports it can produce Ebola cure [Globes, Tel Aviv, Israel :: ]

Sept. 07--Protalix Biotherapeutics IncIn the recent outbreak of Ebola mainly in West Africa, a US citizen who contracted the disease successfully recovered. He was probably saved by an experimental Canadian drug whose stocks are depleted.However, Karmiel-based ... [Published BusinessWeek - Sep 07 2014]
First reported Sep 04 2014 - Updated Sep 05 2014 - 1 reports

Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference

CARMIEL, Israel, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) ( TASE:PLX ), today announced that Yossi Maimon, the Company's Chief Financial Officer, will present at the Rodman & Renshaw 16 th Annual Global Investment ... [Published Street Sweeper - Sep 04 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ taliglucerase alfa for Injection, for Intravenous Use...

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ taliglucerase alfa for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease By a News Reporter-Staff News Editor at Biotech Week -- Pfizer ... [Published Street Sweeper - Sep 05 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 3 reports

FDA Approves Pediatric Indication for Elelyso (taliglucerase alfa)

Pfizer and Protalix BioTherapeutics reported that the U.S. Food and Drug Administration (FDA) approved Elelyso (taliglucerase alfa) for injection for pediatric patients. The companies said that Elelyso is therefore now indicated for long-term enzyme replacement ... [Published Individual.com - Sep 03 2014]

Quotes

...agreement to be an important step towards developing a successful treatment for chronic hepatitis B," OnCore CSO Michael Sofia said in a statement. "Our objective is to cure chronic hepatitis B, building on our success in hepatitis C at Pharmasset."
...presents during childhood," said Paige Kaplan, MB, BCh, Section of Biochemical Genetics (Metabolic Diseases), Children's Hospital of Philadelphia. "It is important that children with this disease have access to a range of FDA-approved treatment options that are effective."
Protalix shares went up by as much as 18 per cent the following day, until chief executive David Aviezer poured cold water on the idea by saying: "We have no information about the drug, no connection with the manufacturers. We also have no genetic information about the drug or the rights to use it."
"In theory, we probably could also produce the antibody used for treating Ebola in our plant cell system," he said. "Based on our technology and their technology we believe this can be done."

More Content

All (76) | News (53) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (2) | Press Releases (12)
sort by: Date | Relevance
New Products for pharmacists 10-10-2014 [Published Drugtopics.com - Sep 30 2014]
PRE 14A - Protalix BioTherapeutics, Inc. (00010... [Published SEC - Sep 29 2014]
PROTALIX BIOTHERAPEUTICS : Change in Directors ... [Published 4 Traders - Sep 29 2014]
Protalix BioTherapeutics names Moshe Manor as CEO [Published Individual.com - Sep 29 2014]
Protalix BioTherapeutics Appoints Moshe Manor a... [Published GlobeNewswire: Advertising News - Sep 29 2014]
Protalix BioTherapeutics Short Interest Up 1.3%... [Published American Banking News - Sep 25 2014]
Bronchopulmonary Dysplasia and Respiratory Sync... [Published Myrtle Beach Sun News - Sep 24 2014]
Hunt for next Sovaldi leads to $150M deal, Poxe... [Published FierceBiotech - Sep 11 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Pharmacy Choice - Sep 10 2014]
FDA News Roundup: Merck, UCB, Pfizer, Ipsen, An... [Published Pharmaceutical Online - Sep 09 2014]
Protalix share price slumps on Ebola vaccine do... [Published City A.M. - Sep 08 2014]
Company Update: Alexion Pharmaceuticals Inc (NA... [Published BioSpace - Sep 08 2014]
With killer virus Ebola out of control, Israel'... [Published Wall Street Business Network - Sep 08 2014]
Protalix Shares Jump on Report of Ebola Drug Te... [Published Hamodia - Sep 08 2014]
BRIEF: Protalix jumps on reports it can produce... [Published BusinessWeek - Sep 07 2014]
Protalix shares surge (briefly) on possible Ebo... [Published Haaretz - Sep 07 2014]
Israeli Company Reports It is Ready to Mass-Pro... [Published Cutting Edge News - Sep 07 2014]
Protalix shares wipe out gains as CEO clarifies... [Published AlertNet - Sep 07 2014]
Protalix shares jump on report of possible Ebol... [Published The Malaysian Insider :: Business - Sep 07 2014]
Protalix shares jump on report of possible Ebol... [Published The Malaysian Insider - Sep 07 2014]
Protalix jumps on reports it can produce Ebola ... [Published Globes - Sep 07 2014]
Protalix shares jump on report of possible Ebol... [Published DailyMe.Com - Sep 07 2014]
Israeli company says it can produce experimenta... [Published The Times Of Israel - Sep 06 2014]
Reco Pharma Says Trial Study Not Seen Reaching ... [Published BioMedReports - Sep 05 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Street Sweeper - Sep 05 2014]
Kamada plunges on lung treatment results [Published Globes - Sep 04 2014]
Foamix sets terms for $71m Nasdaq IPO [Published Globes - Sep 04 2014]
Protalix BioTherapeutics to Present at the Rodm... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Protalix BioTherapeutics to Present at the Rodm... [Published Street Sweeper - Sep 04 2014]
Stock Update (NYSE:PFE): Pfizer Invites Public ... [Published Vision Monday - Sep 03 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Protalix shares jump on report of possible Ebol... [Published The Malaysian Insider - Sep 07 2014]
Shares in Israeli biotech company Protalix jumped on Sunday following a news report that its technology could be used to develop an Ebola treatment similar to the experimental drug ZMapp, which has shown promising results in recent trials.Israel's Channel ...
FDA approves Pfizer and Protalix's Elelyso to t... [Published PBR - News - Aug 29 2014]
The US Food and Drug Administration (FDA) has granted approval for Pfizer and Protalix BioTherapeutics' Elelyso (taliglucerase alfa) for injection to treat adult and pediatric patients with confirmed diagnosis of Type 1 Gaucher disease. ...
Pfizer and Protalix BioTherapeutics Announce FD... [Published Business Wire Health News - Aug 28 2014]
NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric ...
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
Research and Markets: Nerve Gas & Pesticide Poi... [Published Business Wire Manufacturing News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zsmp3h/nerve_gas_and) has announced the addition of the "Nerve Gas & Pesticide Poisoning - Pipeline Review, H1 2014" report to their offering. This report provides ...
1 2

Press Releases

sort by: Date | Relevance
Protalix BioTherapeutics Appoints Moshe Manor a... [Published GlobeNewswire: Advertising News - Sep 29 2014]
Protalix BioTherapeutics to Present at the Rodm... [Published GlobeNewswire: Acquisitions News - Sep 04 2014]
Protalix Announces Conference Call to Discuss E... [Published GlobeNewswire: Nonprofit News - Aug 28 2014]
Protalix Announces New Data on ELELYSO(TM) (tal... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Protalix BioTherapeutics Announces New Data on ... [Published GlobeNewswire: Advertising News - Jun 23 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.